Literature DB >> 11302336

Analysis of genomic rearrangements associated with EGRFvIII expression suggests involvement of Alu repeat elements.

L Frederick1, G Eley, X Y Wang, C D James.   

Abstract

We have developed a polymerase chain reaction (PCR)-based strategy for the synthesis and analysis of rearranged epidermal growth factor receptor (EGFR) fragments associated with the vIII mutant receptor expressed in glioblastomas with EGFR amplification. The sequencing of aberrant tumor fragments showed that intragenic deletion rearrangements consistently involve an approximately 600-bp region in intron 7 of EGFR and several rearrangement sites interspersed throughout the large (>100 kb) first intron of this gene. Examination of the intron 7 breakpoint region revealed an Alu repeat element, and all intron 7 rearrangement sites were located within or downstream of this repeat sequence. Analysis of intron 1 for similar sequences resulted in the identification of 11 sites containing >80% homology with parts of the Alu element in intron 7. Reverse transcriptase-PCR and/or Western analysis of the tumors showed the presence of EGFRvIII cDNAs and/or proteins, respectively, in all cases for which a rearranged genomic fragment was generated by long-range PCR. Collectively, these data suggest that EGFR rearrangements, associated with the synthesis of the most common EGFR mutant, are mediated by a specific sequence element.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11302336      PMCID: PMC1920493          DOI: 10.1093/neuonc/2.3.159

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  30 in total

1.  Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter.

Authors:  Khatri Latha; Ming Li; Vaibhav Chumbalkar; Anupama Gururaj; YeoHyeon Hwang; Sumana Dakeng; Raymond Sawaya; Kenneth Aldape; Webster K Cavenee; Oliver Bogler; Frank B Furnari
Journal:  Int J Cancer       Date:  2012-07-09       Impact factor: 7.396

2.  DNA glycosylase activity and cell proliferation are key factors in modulating homologous recombination in vivo.

Authors:  Orsolya Kiraly; Guanyu Gong; Megan D Roytman; Yoshiyuki Yamada; Leona D Samson; Bevin P Engelward
Journal:  Carcinogenesis       Date:  2014-08-25       Impact factor: 4.944

3.  Combination of phosphorylated and truncated EGFR correlates with higher tumor and nodal stage in head and neck cancer.

Authors:  James Keller; Kenneth R Shroyer; Shishir K Batajoo; Hong-Ling Zhao; Li Ming Dong; Michael J Hayman; Edward L Chan
Journal:  Cancer Invest       Date:  2010-09-27       Impact factor: 2.176

Review 4.  Targeted therapy for malignant glioma patients: lessons learned and the road ahead.

Authors:  Tiffany T Huang; Shawn M Sarkaria; Timothy F Cloughesy; Paul S Mischel
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

5.  Cetuximab induces mitochondrial translocalization of EGFRvIII, but not EGFR: involvement of mitochondria in tumor drug resistance?

Authors:  Agnieszka Dreier; Stefan Barth; Anand Goswami; Joachim Weis
Journal:  Tumour Biol       Date:  2011-10-11

Review 6.  Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.

Authors:  Adam M Swartz; Qi-Jing Li; John H Sampson
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

7.  Mapping of genomic EGFRvIII deletions in glioblastoma: insight into rearrangement mechanisms and biomarker development.

Authors:  Tomoyuki Koga; Bin Li; Javier M Figueroa; Bing Ren; Clark C Chen; Bob S Carter; Frank B Furnari
Journal:  Neuro Oncol       Date:  2018-09-03       Impact factor: 12.300

8.  Mesenchymal stem cells modified with a single-chain antibody against EGFRvIII successfully inhibit the growth of human xenograft malignant glioma.

Authors:  Irina V Balyasnikova; Sherise D Ferguson; Sadhak Sengupta; Yu Han; Maciej S Lesniak
Journal:  PLoS One       Date:  2010-03-18       Impact factor: 3.240

9.  Quantitative proteomic analysis reveals effects of epidermal growth factor receptor (EGFR) on invasion-promoting proteins secreted by glioblastoma cells.

Authors:  Vineet Sangar; Cory C Funk; Ulrike Kusebauch; David S Campbell; Robert L Moritz; Nathan D Price
Journal:  Mol Cell Proteomics       Date:  2014-07-05       Impact factor: 5.911

10.  Genetic modification of mesenchymal stem cells to express a single-chain antibody against EGFRvIII on the cell surface.

Authors:  Irina V Balyasnikova; Rosa Franco-Gou; J Michael Mathis; Maciej S Lesniak
Journal:  J Tissue Eng Regen Med       Date:  2010-06       Impact factor: 3.963

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.